drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy used to target and eliminate CD19-positive B-ALL cells; reinfused after lymphodepleting chemotherapy.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Tisagenlecleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express an anti-CD19 chimeric antigen receptor; upon binding CD19 on malignant B cells, CAR signaling activates T-cell cytotoxicity (perforin/granzyme) and cytokine-mediated killing, leading to expansion and elimination of CD19-positive cells (with resultant B-cell aplasia).
drug_name
Tisagenlecleucel (Kymriah)
nct_id_drug_ref
NCT05310591